Hapoalim Securities Initiates Coverage on Neurocrine Biosciences (NBIX) with a Buy; Expects Positive Results From DAISY PETAL Trial
Tweet Send to a Friend
Hapoalim Securities initiates covreage on Neurocrine Biosciences (Nasdaq: NBIX) with a Buy. Price target $4.
Hapoalim analyst says, "With Neurocrine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Hapoalim analyst says, "With Neurocrine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
